

CURRICULUM VITAE

Sang-Hee Cho, M.D. & Ph.D.

I. Personal Data

Professor in Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea

Address : Medical Oncology, Chonnam National University Hwasun Hospital

322 Seoyang-Ro, Hwanun-Eup, Hwasun-Gun, Jennam, 519-763, Korrea

Tel .: 82-61-379-7633

Fax.: 82-61-379-8019

E-mail. : shcho@jnu.ac.kr

Medical Licence Number : 58961

* Speciality: Internal Medicine

* Subspeciality: Hematology-Oncology

II. SCHOOL EDUCATION

1990-1996: Preschool and School of Medicine, Chonnam National University, Gwangju, Conferred with Bacheolar of Medicine

1997-1999: Graduate school, Chonnam National University

Majoring in Medicine, Conferred with Master of Medical science

1999-2003: Doctor's Course of Graduate School, Chonnam National University

Majoring in Medicine, Conferred with Doctor of Medical science

III . POSTGRADUATE TRAINING and EXPERIENCE

1996. 3 - 1997. 2: Internship in Chonnam National University Hospital, Gwangju

1997. 3 - 2001. 2: Residency in Department of Internal Medicine, Chonnam National University Hospital, Gwangju

2001. 3 - 2003. 2: Fellowship in Division of Hematology-Oncology,

Department of Internal Medicine, Chonnam National University Hospital

2004. 3 – 2005. 8: Clinical Instructor, Chonnam National University Hospital

2005. 9 – 2006. 2: Full time instructor, Chonnam National Univer Medical School

2006. 2 –2010.3 : Assistant Professor, Chonnam National University Medical School,

Gwangju, KOREA

2010.1 – 2011.12: Research scholar in Microbiology and Immunology lab in Indiana
University, USA

2010.4 – 2015.3 : Associate Professor, Chonnam National University Medical School

2015.4 ~ Present : Professor, Chonnam National University Medical School

2016.1 ~ Present : Director of Clinical trial center in Chonnam National Universtih Hwasun Hospital

IV. Publication

1. Phase II study of adjuvant S-1/cisplatin chemotherapy followed by S-1-based chemoradiotherapy for D2-resected gastric cancer. Shim HJ, Kim KR, Hwang JE, Bae WK, Ryu SY, Park YK, Nam TK, Chung IJ, **Cho SH**. Cancer Chemother Pharmacol. 2016 Feb 5
2. The Prognostic Significance of FGFR4 Gly388 Polymorphism in Esophageal Squamous Cell Carcinoma after Concurrent Chemoradiotherapy. Shim HJ, Shin MH, Kim HN, Kim JH, Hwang JE, Bae WK, Chung IJ, **Cho SH**. Cancer Res Treat. 2016 Jan;48(1):71-9
3. A Prospective Multicenter Study Evaluating Secondary Adrenal Suppression after Antiemetic Dexamethasone Therapy in Cancer Patients Receiving Chemotherapy: A Korean South West **Oncology** Group Study. Han HS, Park JC, Park SY, Lee KT, Bae SB, Kim HJ, Kim S, Yun HJ, Bae WK, Shim HJ, Hwang JE, **Cho SH**, Park MR, Shim H, Kwon J, Choi MK, Kim ST, Lee KH. Oncologist. 2015 Dec;20(12)
4. A Randomized, Double-Blind Pilot Study of Dose Comparison of Ramosetron to Prevent Chemotherapy-Induced Nausea and Vomiting. Kim KR, Kang G, Ki MS, Shim HJ, Hwang JE, Bae WK, Chung IJ, Kim JK, Jeong S, **Cho SH**. Biomed Res Int. 2015;2015:523601
5. Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS). Ryu MH, Baba E, Lee KH, Park YI, Boku N, Hyodo I, Nam BH, Esaki T, Yoo C, Ryoo BY, Song EK, **Cho SH**, Kang WK, Yang SH, Zang DY, Shin DB, Park SR, Shinozaki K, Takano T, Kang YK; SOS study investigators. Ann Oncol. 2015 Oct;26(10):2097-101
6. Prognostic implications of thymidylate synthase gene polymorphisms in patients with advanced small bowel adenocarcinoma treated with first-line fluoropyrimidine-based chemotherapy. Yhim HY, **Cho SH**, Kim SY, Cho IS, Lee KT, Lee WS, Lee SI, Park MR, Park SG, Han HS, Choi YS, Chung IJ, Shim HJ, Lee NR, Song EK, Kim HS, Yim CY. Oncol Rep. 2015 Jul;34(1):155-64
7. The Prognostic Significance of FGFR4 Gly388 Polymorphism in Esophageal Squamous Cell Carcinoma after Concurrent Chemoradiotherapy. Shim HJ, Shin MH, Kim HN, Kim JH, Hwang JE, Bae WK, Chung IJ, **Cho SH**. Cancer Res Treat. 2016 Jan;48(1):71-9

8. Different protein expression associated with chemotherapy response in oropharyngeal cancer according to HPV status. Kim MJ, Ki MS, Kim K, Shim HJ, Hwang JE, Bae WK, Chung IJ, Lee DH, Lee JK, Yoon TM, Lim SC, Chung WK, Jeong JU, Lim HS, Choi YD, **Cho SH**. *BMC Cancer*. 2014 Nov
9. Combination of percutaneous radiofrequency ablation and systemic chemotherapy are effective treatment modalities for metachronous liver metastases from gastric cancer. Hwang JE, Kim SH, Jin J, Hong JY, Kim MJ, Jung SH, Shim HJ, Bae WK, Hwang EC, Kim JW, Shin SS, Jeong O, Park YK, **Cho SH**, Chung IJ. *Clin Exp Metastasis*. 2014 Jan;31(1):25-32
10. Clinical prognostic factors for locally advanced esophageal squamous carcinoma treated after definitive chemoradiotherapy. Kim DE, Kim UJ, Choi WY, Kim MY, Kim SH, Kim MJ, Shim HJ, Hwang JE, Bae WK, Chung IJ, Nam TK, Na KJ, **Cho SH**. *Cancer Res Treat*. 2013 Dec;
11. Determinants of a hopeful attitude among family caregivers in a palliative care setting. Kim SY, Kim JM, Kim SW, Kang HJ, Shin IS, Shim HJ, **Cho SH**, Chung IJ, Yoon JS. *Gen Hosp Psychiatry*. 2014 Mar-Apr;36(2):165-71.
12. Common genetic variants at 1q22 and 10q23 and gastric cancer susceptibility in a Korean population. Song HR, Kim HN, Kweon SS, Choi JS, Shim HJ, **Cho SH**, Chung IJ, Park YK, Kim SH, Choi YD, Joo KW, Shin MH. *Tumour Biol*. 2014
13. Class III β -tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancer. Hwang JE, Hong JY, Kim K, Kim SH, Choi WY, Kim MJ, Jung SH, Shim HJ, Bae WK, Hwang EC, Lee KH, Lee JH, **Cho SH**, Chung IJ. *BMC Cancer*. 2013 Sep 23;13:431
14. Genetic variations in the PRKAA1 and ZBTB20 genes and gastric cancer susceptibility in a Korean population. Song HR, Kim HN, Kweon SS, Choi JS, Shim HJ, **Cho SH**, Chung IJ, Park YK, Kim SH, Choi YD, Joo KW, Shin MH. *Mol Carcinog*. 2013 Nov;52 Suppl 1:E155-60
15. Dendritic cell-based immunotherapy for colon cancer using an HLA-A*0201-restricted cytotoxic T-lymphocyte epitope from tumor-associated antigen 90K. Hee Lee J, Park MS, Hwang JE, **Cho SH**, Bae WK, Shim HJ, Kim DE, Chung IJ. *Cell Mol Immunol*. 2013 May;10(3):275-82
16. Does awareness of terminal status influence survival and quality of life in terminally ill cancer patients? Kim SY, Kim JM, Kim SW, Shin IS, Bae KY, Shim HJ, Hwang JE, Bae WK, **Cho SH**, Chung IJ, Yoon JS. *Psychooncology*. 2013 Oct;22(10):2206-13.
17. Multicenter phase II study of weekly docetaxel, cisplatin, and S-1 (TPS) induction chemotherapy for locally advanced squamous cell cancer of the head and neck. Bae WK, Hwang JE, Shim HJ, **Cho SH**, Lee KH, Han HS, Song EK, Yun HJ, Cho IS, Lee JK, Lim SC, Chung WK, Chung IJ. *BMC Cancer*. 2013 Mar 6;13:102
18. Blockade of VEGFR-1 and VEGFR-2 enhances paclitaxel sensitivity in gastric cancer cells. Hwang JE, Lee JH, Park MR, Kim DE, Bae WK, Shim HJ, **Cho SH**, Chung IJ. *Yonsei Med J*. 2013 Mar 1;54(2):374-80

19. Docetaxel-loaded thermoresponsive conjugated linoleic acid-incorporated poloxamer hydrogel for the suppression of peritoneal metastasis of gastric cancer. Bae WK, Park MS, Lee JH, Hwang JE, Shim HJ, **Cho SH**, Kim DE, Ko HM, Cho CS, Park IK, Chung IJ. *Biomaterials*. 2013 Jan;34(4):1433-41.